Company RDI Project

Research and development of innovative pharmaceutical active substances and products with high added value in the areas of cardiology, oncology and central nervous system diseases.
START DATE: 2017-11-01


 Within the confines of this project, Egis Pharmaceuticals PLC conducts research and development procedures on a number of pharmaceutical active substances and products in the areas of cardiology, oncology and central nervous system diseases. 

These R&D activities include all phases of a long, multi-year pharmaceutical product development process. During this project, certain products will only reach the active substance development stage—while others will see the completion of pharmaceutical technology development.


Results expected:

A number of the products developed in the project are likely to be launched on the market by the end of the project maintenance period.
 Patent applications will be submitted and the project will likely result in numerous publications.


Information on the proposed project:

Principal of the tender: National Research, Development and Innovation Office
Title and code of the call for tender proposals: “Support of business RDI activities”, Vállalati KFI_16
Title and ID of proposed project: “Research and development of innovative, value added APIs and formulated products for cardiovascular, oncological and CNS diseases”, KFI_16-1-2017-0170
Submission date of proposal: 15/02/2017
Date of decision about funding: 08/06/2017
Granted amount and funding intensity in total: HUF 499,800,000 (52.5 %)
Applicant: Egis Pharmaceuticals PLC
Strategic partners:
          ● Medicinal Chemistry Research Group of the Research Center of Natural Science of the Hungarian Academy of Sciences
          ● H-ION Research, Development and Innovation Ltd. 
Time period for project implementation: 01/11/2017 - 31/10/2019
Total costs of the project: HUF 952,000,000

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox